Optimizing the MDS-UPDRS for Early-Stage Parkinson's Disease: New Breakthrough in Neurodegenerative Research

Strategic Insights -

A team of researchers has made significant strides in developing a more effective assessment tool for Parkinson's disease, specifically targeting early-stage patients. By applying a cross-sectional Rasch model to the Parkinson's Progression Markers Initiative (PPMI) untreated PD cohort data, the team identified a sub-score of 15 MDS-UPDRS Part III items focusing on limb-related bradykinesia and rigidity, which demonstrated good measurement properties in early-stage PD. This breakthrough has significant implications for the diagnosis and treatment of Parkinson's disease, a neurodegenerative disorder affecting millions worldwide.

Key Takeaways:

  • The MDS-UPDRS, a widely used assessment tool for Parkinson's disease, was not specifically designed for early-stage patients.
  • A sub-score of 15 MDS-UPDRS Part III items focusing on limb-related bradykinesia and rigidity demonstrated good measurement properties in early-stage PD.
  • The new sub-score targets the onset of clinical signs, representing a milestone in the emergence of impairment in patients' daily functioning.
  • The scale is invariant to symptomatic treatment intake, providing a more accurate evaluation of disease progression.
  • The study utilized data from the Parkinson's Progression Markers Initiative (PPMI) untreated PD cohort, consisting of 423 patients.
  • The research team included Maria Key Prato, Antoine Regnault, Stephane Quere, Anne Benoit, Nathalie J. Massat, and Thomas Morel from UCB and the University of Brussels.
  • The study was funded by UCB, a multinational pharmaceutical company.

Statistics:

  • 423 patients participated in the study, consisting of the Parkinson's Progression Markers Initiative (PPMI) untreated PD cohort.
  • The new sub-score consisted of 15 MDS-UPDRS Part III items focusing on limb-related bradykinesia and rigidity.
  • The scale demonstrated good measurement properties, including a meaningful hierarchy and validity.
  • The study concluded that the onset of clinical signs represents a milestone in the emergence of impairment in patients' daily functioning.

Sources:

  • npj Parkinson's Disease, 2025;11(1):297. "Optimizing the MDS-UPDRS Part III for early-stage Parkinson's: early supportive evidence for a limb-related bradykinesia/rigidity sub-score."
  • Pain & Central Nervous System Week. October 27, 2025; p 1810. "Studies from Maria Key Prato and Co-Authors Have Provided New Information about Parkinson's Disease."